Cancer and diabetes research are increasingly converging around how diseased cells communicate across the body. That focus sharpened again this year as scientists reported new evidence that extracellular vesicles, sometimes called exosomes, may carry signals that help disease processes advance. The latest work adds to a broader effort to understand how those particles could shape metastasis, insulin resistance, and organ damage.
Researchers point to cell-to-cell cargo as the specific mechanism under review
Scientists at Memorial Sloan Kettering Cancer Center reported on June 11, 2026, that human cells can transfer DNA directly to other cells through nanotube-like structures, according to a study indexed by PubMed and published in Cancer Research. The paper described what the authors called a novel form of horizontal gene transfer in human cells, a finding that could matter for diseases driven by genetic instability, including cancer. The study was conducted in cell lines, not in patients, but it added a concrete mechanism for how harmful cellular material might move from one cell to another.
That report arrived alongside a growing body of work on extracellular vesicles, the small membrane-bound particles cells release into blood and other fluids. A July 2026 review indexed by PubMed described the systemic health impact of cancer-associated extracellular vesicles and particles, reflecting how seriously the field is taking their role in disease progression. In cancer research, these particles are already being studied for how they can reshape the tumor environment, help tumors evade immune defenses, and support metastasis.
In diabetes research, vesicles are also drawing attention because they carry RNA, proteins, lipids, and other cargo that can alter how distant tissues respond. Prior work from UC San Diego, summarized by ScienceDaily from a Cell study, described exosomes as a mechanism that can help drive insulin resistance by moving inflammatory signals between tissues. Taken together, the evidence does not show a contagious disease process. It does show that internal cell-to-cell transfer is becoming a central explanation for how disease-related damage may propagate inside the body.
What is confirmed nationally, and what is not yet known at the state or local level
What is confirmed is national and laboratory-based, not tied to a specific consumer-facing geography. The Memorial Sloan Kettering findings involved human cell lines and identified DNA transfer through nanotubes, while multiple cancer and diabetes studies have examined circulating extracellular vesicles in blood, plasma, urine, and tumor environments. Researchers have also reported that vesicles from people with type 2 diabetes can promote more aggressive behavior in breast-cancer organoid models, according to a PubMed-indexed study published last year.
What is not known is how broadly these mechanisms operate across all tumor types, all diabetes complications, or all patients. Researchers have not established that cancer or diabetes “spread” from person to person through these mechanisms. They also have not released evidence that would support using this biology yet as a routine screening tool in local clinics, pharmacies, or hospitals outside research settings.
For readers in the United States, the immediate impact is informational rather than operational. There is no recall, advisory, or public-health restriction tied to this research. Instead, the work helps explain why physicians and scientists are increasingly focused on blood-based biomarkers, tumor-derived vesicles, and metabolic changes that may one day help identify which patients face faster cancer progression or more severe diabetes-related complications.
The broader context is a long-running effort to explain metastasis and metabolic dysfunction
The reason this research matters is that both cancer and diabetes involve body-wide signaling problems that scientists still do not fully understand. In cancer, metastasis remains the deadliest part of the disease, and a 2026 review indexed by PubMed noted that cancer metastasis accounts for about 90% of cancer-related mortality. Researchers have been trying to determine how tumors prepare distant organs, suppress immune responses, and alter neighboring cells before visible spread occurs.
In diabetes, insulin resistance and tissue injury also appear to involve communication between organs rather than damage confined to one site. A 2023 systematic review and meta-analysis from researchers at the University of Copenhagen, summarized by ScienceDaily, concluded that insulin resistance is present in cancer patients and may help tumors grow faster because high insulin levels can act as a growth signal. That work helped reinforce why cancer and metabolic disease are increasingly studied together.
For patients and residents, the practical takeaway is limited but important. The newest studies expand the scientific case that disease-driving signals can move through microscopic cellular cargo, but they do not change current medical guidance on cancer or diabetes screening. What they do offer is a clearer research path for future blood tests, earlier risk detection, and treatments designed to interrupt the messages diseased cells send to the rest of the body.